Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment

1984 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Peter Tyrer
Keyword(s):  
Monoamine Oxidase ◽  
Term Treatment ◽  
Monoamine Oxidase Inhibitors ◽  
Clinical Effects ◽  
Abrupt Withdrawal ◽  
Long Term Treatment

Central and peripheral dopamine beta hydroxylase: Responses to long term treatment with monoamine oxidase inhibitors

1980 ◽  
Vol 19 (9) ◽  
pp. 877-881 ◽  
Author(s):  
Pauline Lerner ◽  
L.F. Major ◽  
P.S. Dendel ◽  
I.C. Campbell ◽  
D.L. Murphy
Keyword(s):  
Monoamine Oxidase ◽  
Term Treatment ◽  
Monoamine Oxidase Inhibitors ◽  
Dopamine Beta Hydroxylase ◽  
Long Term Treatment

Haemodynamic and clinical effects of long-term treatment of essential hypertension with captopril

1983 ◽  
Vol 4 (7) ◽  
pp. 496-501 ◽  
Author(s):  
B. RICCIARDELLI ◽  
M. VOLPE ◽  
B. TRIMARCO ◽  
N. DE LUCA ◽  
A. CUOCOLO ◽  
...  
Keyword(s):  
Essential Hypertension ◽  
Term Treatment ◽  
Clinical Effects ◽  
Long Term Treatment

Pharmacotherapy of dysthymia: review and new findings

1998 ◽  
Vol 13 (4) ◽  
pp. 203-209 ◽  
Author(s):  
M Versiani ◽  
AE Nardi ◽  
I Figueira
Keyword(s):  
Monoamine Oxidase ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Response Rate ◽  
Term Treatment ◽  
Reversible Inhibitors ◽  
Benefit Ratio ◽  
New Findings ◽  
Long Term Treatment

SummaryOpen trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a combination of amitryptiline plus chlordiazepoxide is described. After discontinuation there was a relapse rate of 89.1%. The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Sertraline was studied vs placebo or imipramine in primary dysthymia. Moclobemide, imipramine and placebo were also studied in 315 patients. Mean doses were 650 mg/d of moclobemide and 203.2 mg/d of imipramine. Moclobemide and sertraline were both efficacious and well tolerated. In a long term treatment the clinician should assess the risk-benefit ratio. Dysthymic patients are very sensitive to unwanted effects and compliance is a serious issue.

Hypothalamic-Pituitary-Adrenocortical Axis Changes in the Rat after Long-Term Treatment with the Reversible Monoamine Oxidase-A Inhibitor Moclobemide

1994 ◽  
Vol 60 (5) ◽  
pp. 509-519 ◽  
Author(s):  
Johannes M.H.M. Reul ◽  
Marta S. Labeur ◽  
Dimitri E. Grigoriadis ◽  
Errol B. De Souza ◽  
Florian Holsboer
Keyword(s):  
Monoamine Oxidase ◽  
Term Treatment ◽  
Monoamine Oxidase A ◽  
Long Term Treatment
Sign in / Sign up

Export Citation Format

Share Document